These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 11091277)
1. The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes. Soto M; Alonso C; Requena JM Clin Exp Immunol; 2000 Nov; 122(2):212-8. PubMed ID: 11091277 [TBL] [Abstract][Full Text] [Related]
2. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers. Iborra S; Abánades DR; Parody N; Carrión J; Risueño RM; Pineda MA; Bonay P; Alonso C; Soto M Clin Exp Immunol; 2007 Nov; 150(2):375-85. PubMed ID: 17900304 [TBL] [Abstract][Full Text] [Related]
3. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Iborra S; Soto M; Carrión J; Nieto A; Fernández E; Alonso C; Requena JM Infect Immun; 2003 Nov; 71(11):6562-72. PubMed ID: 14573678 [TBL] [Abstract][Full Text] [Related]
4. Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters. Pereira L; Abbehusen M; Teixeira C; Cunha J; Nascimento IP; Fukutani K; dos-Santos W; Barral A; de Oliveira CI; Barral-Netto M; Soto M; Brodskyn CI PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003490. PubMed ID: 25642946 [TBL] [Abstract][Full Text] [Related]
5. During active viscerocutaneous leishmaniasis the anti-P2 humoral response is specifically triggered by the parasite P proteins. Soto M; Requena JM; Quijada L; Angel SO; Gomez LC; Guzman F; Patarroyo ME; Alonso C Clin Exp Immunol; 1995 May; 100(2):246-52. PubMed ID: 7743663 [TBL] [Abstract][Full Text] [Related]
6. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. Stäger S; Smith DF; Kaye PM J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis. de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection. Parody N; Soto M; Requena JM; Alonso C Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032 [TBL] [Abstract][Full Text] [Related]
13. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303 [TBL] [Abstract][Full Text] [Related]
15. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum. Pirdel L; Farajnia S Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153 [TBL] [Abstract][Full Text] [Related]
16. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. Silvestre R; Cordeiro-Da-Silva A; Santarém N; Vergnes B; Sereno D; Ouaissi A J Immunol; 2007 Sep; 179(5):3161-70. PubMed ID: 17709531 [TBL] [Abstract][Full Text] [Related]
17. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731 [TBL] [Abstract][Full Text] [Related]
18. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related]
19. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis. Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291 [TBL] [Abstract][Full Text] [Related]
20. Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis. Dias DS; Martins VT; Ribeiro PAF; Ramos FF; Lage DP; Tavares GSV; Mendonça DVC; Chávez-Fumagalli MA; Oliveira JS; Silva ES; Gomes DA; Rodrigues MA; Duarte MC; Galdino AS; Menezes-Souza D; Coelho EAF Parasitology; 2018 May; 145(6):740-751. PubMed ID: 29113597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]